Literature DB >> 19339347

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials.

Richard A Koup1, Laurie Lamoreaux, David Zarkowsky, Robert T Bailer, C Richter King, Jason G D Gall, Douglas E Brough, Barney S Graham, Mario Roederer.   

Abstract

The magnitude and character of adenovirus serotype 5 (Ad5)-specific T cells were determined in volunteers with and without preexisting neutralizing antibodies (NAs) to Ad5 who received replication-defective Ad5 (rAd5)-based human immunodeficiency virus vaccines. There was no correlation between T-cell responses and NAs to Ad5. There was no increase in magnitude or activation state of Ad5-specific CD4(+) T cells at time points where antibodies to Ad5 and T-cell responses to the recombinant gene products could be measured. These data indicate that rAd5-based vaccines containing deletions in the E1, E3, and E4 regions do not induce appreciable expansion of vector-specific CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339347      PMCID: PMC2687372          DOI: 10.1128/JVI.00384-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

Review 2.  Biology of adenovirus and its use as a vector for gene therapy.

Authors:  Michael J McConnell; Michael J Imperiale
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

Review 3.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

Authors:  Dan H Barouch; Gary J Nabel
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

4.  Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications.

Authors:  K Ebner; W Pinsker; T Lion
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.

Authors:  D E Brough; A Lizonova; C Hsu; V A Kulesa; I Kovesdi
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.

Authors:  Y Yang; K U Jooss; Q Su; H C Ertl; J M Wilson
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

8.  Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein.

Authors:  D E Brough; V Cleghon; D F Klessig
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

9.  Multiple functions of the adenovirus DNA-binding protein are required for efficient viral DNA synthesis.

Authors:  D E Brough; G Droguett; M S Horwitz; D F Klessig
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

10.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Authors:  M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

View more
  16 in total

Review 1.  Cofactors that may influence vaccine responses.

Authors:  Guy de Bruyn
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 2.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Authors:  Nicole Frahm; Allan C DeCamp; David P Friedrich; Donald K Carter; Olivier D Defawe; James G Kublin; Danilo R Casimiro; Ann Duerr; Michael N Robertson; Susan P Buchbinder; Yunda Huang; Gregory A Spies; Stephen C De Rosa; M Juliana McElrath
Journal:  J Clin Invest       Date:  2011-12-27       Impact factor: 14.808

4.  Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys.

Authors:  Yue Sun; Robert T Bailer; Srinivas S Rao; John R Mascola; Gary J Nabel; Richard A Koup; Norman L Letvin
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

5.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Authors:  Glenda E Gray; Zoe Moodie; Barbara Metch; Peter B Gilbert; Linda-Gail Bekker; Gavin Churchyard; Maphoshane Nchabeleng; Koleka Mlisana; Fatima Laher; Surita Roux; Kathryn Mngadi; Craig Innes; Matsontso Mathebula; Mary Allen; M Julie McElrath; Michael Robertson; James Kublin; Lawrence Corey
Journal:  Lancet Infect Dis       Date:  2014-02-20       Impact factor: 25.071

Review 6.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

7.  HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.

Authors:  Stephen C De Rosa; Evan P Thomas; John Bui; Yunda Huang; Allan deCamp; Cecilia Morgan; Spyros A Kalams; Georgia D Tomaras; Rama Akondy; Rafi Ahmed; Chuen-Yen Lau; Barney S Graham; Gary J Nabel; M Juliana McElrath
Journal:  J Immunol       Date:  2011-08-15       Impact factor: 5.422

Review 8.  HIV-specific CD4 T cells and immune control of viral replication.

Authors:  Filippos Porichis; Daniel E Kaufmann
Journal:  Curr Opin HIV AIDS       Date:  2011-05       Impact factor: 4.283

9.  Characterization of human adenovirus 35 and derivation of complex vectors.

Authors:  Duncan McVey; Mohammed Zuber; Damodar Ettyreddy; Christopher D Reiter; Douglas E Brough; Gary J Nabel; C Richter King; Jason G D Gall
Journal:  Virol J       Date:  2010-10-19       Impact factor: 4.099

10.  Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.

Authors:  Adel Benlahrech; Julian Harris; Andrea Meiser; Timos Papagatsias; Julia Hornig; Peter Hayes; Andre Lieber; Takis Athanasopoulos; Veronique Bachy; Eszter Csomor; Rod Daniels; Kerry Fisher; Frances Gotch; Len Seymour; Karen Logan; Romina Barbagallo; Linda Klavinskis; George Dickson; Steven Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.